These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 29470806)

  • 1. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
    Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
    Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India.
    Mannan AU; Singh J; Lakshmikeshava R; Thota N; Singh S; Sowmya TS; Mishra A; Sinha A; Deshwal S; Soni MR; Chandrasekar A; Ramesh B; Ramamurthy B; Padhi S; Manek P; Ramalingam R; Kapoor S; Ghosh M; Sankaran S; Ghosh A; Veeramachaneni V; Ramamoorthy P; Hariharan R; Subramanian K
    J Hum Genet; 2016 Jun; 61(6):515-22. PubMed ID: 26911350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
    BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
    Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
    Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
    Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U
    Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Donenberg T; Ahmed H; Royer R; Zhang S; Narod SA; George S; Akbari MR; Ali J; Hurley J
    Breast Cancer Res Treat; 2016 Aug; 159(1):131-8. PubMed ID: 27469594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
    Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
    Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
    BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.